Establishment and characterization of two 5-fluorouracil-resistant hepatocellular carcinoma cell lines. 2012

Kazuya Uchibori, and Atsushi Kasamatsu, and Masahiko Sunaga, and Satoshi Yokota, and Tomoya Sakurada, and Eriko Kobayashi, and Masaharu Yoshikawa, and Katsuhiro Uzawa, and Shiro Ueda, and Hideki Tanzawa, and Nobunori Sato
Department of Clinical Education and Research, Graduate School of Pharmaceutical Sciences, Chiba University, Chiba 260-8670, Japan.

5-Fluorouracil (5-FU) chemotherapy is the first choice treatment for advanced hepatocellular carcinoma (HCC), and resistance is the major obstacle to successful treatment. Recent studies have reported that epithelial-to-mesenchymal transition (EMT) is associated with chemoresistance in cancers. We speculated that EMT and 5-FU metabolism are related to the mechanism of 5-FU resistance. First, two 5-FU-resistant cell lines, HLF-R4 and HLF-R10, were established from the HLF undifferentiated human HCC cell line. Whereas cell growth was similar in the HLF and HLF-R cell lines, HLF-Rs are about 4- and 10-fold more resistant compared with the HLF cells; thus, we named these cell lines HLF-R4 and HLF-R10, respectively. The terminal deoxyribonucleotidyl transferase-mediated dUTP nick end labeling assay also showed a dramatically decreased number of apoptotic cells in the HLF-Rs after treatment with 5-FU. We next assessed the characteristics of the HLF, HLF-R4 and HLF-R10 cells. Consistent with our hypothesis, the HLF-Rs had typical morphologic phenotypes of EMT, loss of cell-cell adhesion, spindle-shaped morphology and increased formation of pseudopodia. Real-time quantitative reverse transcriptase polymerase chain reaction data showed downregulated E-cadherin and upregulated Twist-1 and also indicated that EMT changes occurred in the HLF-Rs. We also found decreased ribonucleotide reductase and increased multidrug resistance protein 5 genes in the HLF-R cells. Our results suggested that the metabolism of EMT and 5-FU has important roles in 5-FU chemoresistance in the HLF-R cells, and that the HLF-R cells would be useful in vitro models for understanding the 5-FU-resistant mechanisms in HCC.

UI MeSH Term Description Entries
D008113 Liver Neoplasms Tumors or cancer of the LIVER. Cancer of Liver,Hepatic Cancer,Liver Cancer,Cancer of the Liver,Cancer, Hepatocellular,Hepatic Neoplasms,Hepatocellular Cancer,Neoplasms, Hepatic,Neoplasms, Liver,Cancer, Hepatic,Cancer, Liver,Cancers, Hepatic,Cancers, Hepatocellular,Cancers, Liver,Hepatic Cancers,Hepatic Neoplasm,Hepatocellular Cancers,Liver Cancers,Liver Neoplasm,Neoplasm, Hepatic,Neoplasm, Liver
D005472 Fluorouracil A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid. 5-FU,5-FU Lederle,5-FU Medac,5-Fluorouracil,5-Fluorouracil-Biosyn,5-HU Hexal,5FU,Adrucil,Carac,Efudex,Efudix,Fluoro-Uracile ICN,Fluoroplex,Fluorouracil Mononitrate,Fluorouracil Monopotassium Salt,Fluorouracil Monosodium Salt,Fluorouracil Potassium Salt,Fluorouracil-GRY,Fluorouracile Dakota,Fluorouracilo Ferrer Far,Fluoruracil,Fluracedyl,Flurodex,Haemato-FU,Neofluor,Onkofluor,Ribofluor,5 FU Lederle,5 FU Medac,5 Fluorouracil,5 Fluorouracil Biosyn,5 HU Hexal,Dakota, Fluorouracile,Fluoro Uracile ICN,Fluorouracil GRY,Haemato FU
D006528 Carcinoma, Hepatocellular A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested. Hepatocellular Carcinoma,Hepatoma,Liver Cancer, Adult,Liver Cell Carcinoma,Liver Cell Carcinoma, Adult,Adult Liver Cancer,Adult Liver Cancers,Cancer, Adult Liver,Cancers, Adult Liver,Carcinoma, Liver Cell,Carcinomas, Hepatocellular,Carcinomas, Liver Cell,Cell Carcinoma, Liver,Cell Carcinomas, Liver,Hepatocellular Carcinomas,Hepatomas,Liver Cancers, Adult,Liver Cell Carcinomas
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000964 Antimetabolites, Antineoplastic Antimetabolites that are useful in cancer chemotherapy. Antineoplastic Antimetabolites
D045744 Cell Line, Tumor A cell line derived from cultured tumor cells. Tumor Cell Line,Cell Lines, Tumor,Line, Tumor Cell,Lines, Tumor Cell,Tumor Cell Lines
D048708 Cell Growth Processes Processes required for CELL ENLARGEMENT and CELL PROLIFERATION. Processes, Cell Growth
D058750 Epithelial-Mesenchymal Transition Phenotypic changes of EPITHELIAL CELLS to MESENCHYME type, which increase cell mobility critical in many developmental processes such as NEURAL TUBE development. NEOPLASM METASTASIS and DISEASE PROGRESSION may also induce this transition. Epithelial-Mesenchymal Transformation,Epithelial Mesenchymal Transformation,Epithelial Mesenchymal Transition,Transformation, Epithelial-Mesenchymal,Transition, Epithelial-Mesenchymal
D019008 Drug Resistance, Neoplasm Resistance or diminished response of a neoplasm to an antineoplastic agent in humans, animals, or cell or tissue cultures. Antibiotic Resistance, Neoplasm,Antineoplastic Drug Resistance,Drug Resistance, Antineoplastic,Antineoplastic Agent Resistance,Neoplasm Drug Resistance,Resistance, Antineoplastic Agent,Resistance, Antineoplastic Drug
D020287 In Situ Nick-End Labeling An in situ method for detecting areas of DNA which are nicked during APOPTOSIS. Terminal deoxynucleotidyl transferase is used to add labeled dUTP, in a template-independent manner, to the 3 prime OH ends of either single- or double-stranded DNA. The terminal deoxynucleotidyl transferase nick end labeling, or TUNEL, assay labels apoptosis on a single-cell level, making it more sensitive than agarose gel electrophoresis for analysis of DNA FRAGMENTATION. Nick-End Labeling, In Situ,TUNEL,In Situ Nick End Labeling,In Situ Nick End Labelling,In Situ Nick End-Labeling,In Situ Nick End-Labelling,In Situ Nick-End Labelling,Nick End-Labeling, In Situ,Nick End-Labelling, In Situ,Nick-End Labelling, In Situ,Nick End Labeling, In Situ,Nick End Labelling, In Situ

Related Publications

Kazuya Uchibori, and Atsushi Kasamatsu, and Masahiko Sunaga, and Satoshi Yokota, and Tomoya Sakurada, and Eriko Kobayashi, and Masaharu Yoshikawa, and Katsuhiro Uzawa, and Shiro Ueda, and Hideki Tanzawa, and Nobunori Sato
January 2008, Chemotherapy,
Kazuya Uchibori, and Atsushi Kasamatsu, and Masahiko Sunaga, and Satoshi Yokota, and Tomoya Sakurada, and Eriko Kobayashi, and Masaharu Yoshikawa, and Katsuhiro Uzawa, and Shiro Ueda, and Hideki Tanzawa, and Nobunori Sato
September 2010, International journal of oncology,
Kazuya Uchibori, and Atsushi Kasamatsu, and Masahiko Sunaga, and Satoshi Yokota, and Tomoya Sakurada, and Eriko Kobayashi, and Masaharu Yoshikawa, and Katsuhiro Uzawa, and Shiro Ueda, and Hideki Tanzawa, and Nobunori Sato
January 2012, Asian Pacific journal of cancer prevention : APJCP,
Kazuya Uchibori, and Atsushi Kasamatsu, and Masahiko Sunaga, and Satoshi Yokota, and Tomoya Sakurada, and Eriko Kobayashi, and Masaharu Yoshikawa, and Katsuhiro Uzawa, and Shiro Ueda, and Hideki Tanzawa, and Nobunori Sato
January 2024, Frontiers in veterinary science,
Kazuya Uchibori, and Atsushi Kasamatsu, and Masahiko Sunaga, and Satoshi Yokota, and Tomoya Sakurada, and Eriko Kobayashi, and Masaharu Yoshikawa, and Katsuhiro Uzawa, and Shiro Ueda, and Hideki Tanzawa, and Nobunori Sato
April 2014, International journal of oncology,
Kazuya Uchibori, and Atsushi Kasamatsu, and Masahiko Sunaga, and Satoshi Yokota, and Tomoya Sakurada, and Eriko Kobayashi, and Masaharu Yoshikawa, and Katsuhiro Uzawa, and Shiro Ueda, and Hideki Tanzawa, and Nobunori Sato
June 1990, Laboratory investigation; a journal of technical methods and pathology,
Kazuya Uchibori, and Atsushi Kasamatsu, and Masahiko Sunaga, and Satoshi Yokota, and Tomoya Sakurada, and Eriko Kobayashi, and Masaharu Yoshikawa, and Katsuhiro Uzawa, and Shiro Ueda, and Hideki Tanzawa, and Nobunori Sato
March 2018, Oncotarget,
Kazuya Uchibori, and Atsushi Kasamatsu, and Masahiko Sunaga, and Satoshi Yokota, and Tomoya Sakurada, and Eriko Kobayashi, and Masaharu Yoshikawa, and Katsuhiro Uzawa, and Shiro Ueda, and Hideki Tanzawa, and Nobunori Sato
October 2000, Cancer letters,
Kazuya Uchibori, and Atsushi Kasamatsu, and Masahiko Sunaga, and Satoshi Yokota, and Tomoya Sakurada, and Eriko Kobayashi, and Masaharu Yoshikawa, and Katsuhiro Uzawa, and Shiro Ueda, and Hideki Tanzawa, and Nobunori Sato
November 1982, The Journal of urology,
Kazuya Uchibori, and Atsushi Kasamatsu, and Masahiko Sunaga, and Satoshi Yokota, and Tomoya Sakurada, and Eriko Kobayashi, and Masaharu Yoshikawa, and Katsuhiro Uzawa, and Shiro Ueda, and Hideki Tanzawa, and Nobunori Sato
February 1993, Bollettino della Societa italiana di biologia sperimentale,
Copied contents to your clipboard!